Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALC NASDAQ:ENTX NASDAQ:IMA NASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$0.87-2.7%$0.69$0.46▼$7.20$13.70M0.97327,524 shs91,867 shsENTXEntera Bio$1.23+6.0%$1.22$0.91▼$3.22$60.63M1.5662,992 shs45,819 shsIMAImageneBio$5.62-1.6%$5.59$3.94▼$18.00$59.88M0.7215,336 shs13,307 shsPMVPPMV Pharmaceuticals$1.11+1.8%$1.30$0.96▼$1.88$59.20M1.36290,074 shs120,524 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica-2.75%-18.21%+25.67%+4.46%-52.10%ENTXEntera Bio+6.03%+4.24%-4.65%-3.15%-41.43%IMAImageneBio-1.58%-0.53%-2.60%-4.91%-66.55%PMVPPMV Pharmaceuticals+1.83%-0.89%-13.95%-28.85%-1.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$0.87-2.7%$0.69$0.46▼$7.20$13.70M0.97327,524 shs91,867 shsENTXEntera Bio$1.23+6.0%$1.22$0.91▼$3.22$60.63M1.5662,992 shs45,819 shsIMAImageneBio$5.62-1.6%$5.59$3.94▼$18.00$59.88M0.7215,336 shs13,307 shsPMVPPMV Pharmaceuticals$1.11+1.8%$1.30$0.96▼$1.88$59.20M1.36290,074 shs120,524 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica-2.75%-18.21%+25.67%+4.46%-52.10%ENTXEntera Bio+6.03%+4.24%-4.65%-3.15%-41.43%IMAImageneBio-1.58%-0.53%-2.60%-4.91%-66.55%PMVPPMV Pharmaceuticals+1.83%-0.89%-13.95%-28.85%-1.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 2.00Hold$10.001,053.40% UpsideENTXEntera Bio 2.00Hold$9.00631.71% UpsideIMAImageneBio 2.00Hold$26.50371.53% UpsidePMVPPMV Pharmaceuticals 2.67Moderate Buy$5.00350.45% UpsideCurrent Analyst Ratings BreakdownLatest CALC, IMA, ENTX, and PMVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026PMVPPMV Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$6.00 ➝ $5.005/11/2026IMAImageneBio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform4/29/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026PMVPPMV Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A($0.46) per shareN/AENTXEntera Bio$40K1,515.67N/AN/A$0.29 per share4.24IMAImageneBio$800K74.82N/AN/A$11.91 per share0.47PMVPPMV PharmaceuticalsN/AN/AN/AN/A$1.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)ENTXEntera Bio-$11.44M-$0.27N/AN/AN/AN/A-83.31%-70.83%8/14/2026 (Estimated)IMAImageneBio-$45.35M-$5.79N/AN/AN/AN/A-38.96%-34.60%N/APMVPPMV Pharmaceuticals-$77.74M-$1.49N/AN/AN/AN/A-68.98%-62.70%8/6/2026 (Estimated)Latest CALC, IMA, ENTX, and PMVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PMVPPMV Pharmaceuticals-$0.41-$0.34+$0.07-$0.34N/AN/A5/8/2026Q1 2026ENTXEntera Bio-$0.08-$0.07+$0.01$0.07N/AN/A5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/A3/27/2026Q4 2025ENTXEntera Bio-$0.09-$0.07+$0.02$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedicaN/A1.611.61ENTXEntera BioN/A7.937.93IMAImageneBioN/A18.3918.39PMVPPMV PharmaceuticalsN/A11.1411.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/AENTXEntera Bio14.11%IMAImageneBio75.00%PMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%ENTXEntera Bio10.57%IMAImageneBio5.94%PMVPPMV Pharmaceuticals7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3015.80 million9.23 millionNo DataENTXEntera Bio2049.29 million44.08 millionOptionableIMAImageneBio7010.65 million10.02 millionNot OptionablePMVPPMV Pharmaceuticals5053.33 million49.30 millionOptionableCALC, IMA, ENTX, and PMVP HeadlinesRecent News About These CompaniesPMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerJune 10 at 10:35 AM | zacks.comWhy PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial ActivityJune 3, 2026 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial ActivityJune 2, 2026 | insidermonkey.comPMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84April 28, 2026 | msn.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | finanznachrichten.dePMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | globenewswire.comIs PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?April 20, 2026 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.84%March 9, 2026 | aaii.comAPMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate HighlightsMarch 6, 2026 | globenewswire.comNew England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid TumorsFebruary 27, 2026 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 8.04%February 27, 2026 | aaii.comAPMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial ComparisonNovember 23, 2025 | defenseworld.netDPMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)November 12, 2025 | msn.comPMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate HighlightsNovember 12, 2025 | markets.businessinsider.comIs PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?October 28, 2025 | finance.yahoo.comPMV Pharmaceuticals stock rises on positive cancer drug trial dataOctober 24, 2025 | in.investing.comPMV Pharmaceuticals announces updated rezatapopt monotherapy interim dataOctober 24, 2025 | msn.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a ...October 24, 2025 | finanznachrichten.dePMV Pharma Presents Promising Phase 2 Trial Results for Rezatapopt at 2025 AACR-NCI-EORTC ConferenceOctober 24, 2025 | quiverquant.comQPMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C MutationOctober 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026AI’s Biggest Bottleneck Could Make These 2 Stocks SoarBy Jeffrey Neal Johnson | May 28, 2026Deere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookBy Chris Markoch | May 22, 2026Viking Sails to All-Time Highs—Fundamentals Signal More to ComeBy Chris Markoch | May 15, 2026Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?By Sam Quirke | June 6, 2026CALC, IMA, ENTX, and PMVP Company DescriptionsCalciMedica NASDAQ:CALC$0.87 -0.02 (-2.75%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.88 +0.01 (+1.50%) As of 06/12/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Entera Bio NASDAQ:ENTX$1.23 +0.07 (+6.03%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.23 0.00 (-0.41%) As of 06/12/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.ImageneBio NASDAQ:IMA$5.62 -0.09 (-1.58%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$5.62 +0.00 (+0.09%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.PMV Pharmaceuticals NASDAQ:PMVP$1.11 +0.02 (+1.83%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.12 +0.01 (+0.63%) As of 06/12/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
